Literature DB >> 27860536

The advantageous role of annexin A1 in cardiovascular disease.

Renske de Jong1,2, Giovanna Leoni1,2, Maik Drechsler1,2,3, Oliver Soehnlein1,2,3.   

Abstract

The inflammatory response protects the human body against infection and injury. However, uncontrolled and unresolved inflammation can lead to tissue damage and chronic inflammatory diseases. Therefore, active resolution of inflammation is essential to restore tissue homeostasis. This review focuses on the pro-resolving molecule annexin A1 (ANXA1) and its derived peptides. Mechanisms instructed by ANXA1 are multidisciplinary and affect leukocytes as well as endothelial cells and tissue resident cells like macrophages and mast cells. ANXA1 has an outstanding role in limiting leukocyte recruitment and different aspects of ANXA1 as modulator of the leukocyte adhesion cascade are discussed here. Additionally, this review details the therapeutic relevance of ANXA1 and its derived peptides in cardiovascular diseases since atherosclerosis stands out as a chronic inflammatory disease with impaired resolution and continuous leukocyte recruitment.

Entities:  

Keywords:  Ac2–26; annexin A1; atherosclerosis; cardiovascular diseases; leukocyte recruitment; myocardial infarction; resolution of inflammation; stroke

Mesh：

Substances：

Year:  2016        PMID： 27860536      PMCID： PMC5479459          DOI： 10.1080/19336918.2016.1259059

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN： 1933-6918            Impact factor:   3.405


  121 in total

1.  Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment.

Authors:  M D'Amico; C Di Filippo; M La; E Solito; P G McLean; R J Flower; S M Oliani; M Perretti
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

2.  Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair.

Authors:  Giovanna Leoni; Philipp-Alexander Neumann; Nazila Kamaly; Miguel Quiros; Hikaru Nishio; Hefin R Jones; Ronen Sumagin; Roland S Hilgarth; Ashfaqul Alam; Gabrielle Fredman; Ioannis Argyris; Emile Rijcken; Dennis Kusters; Chris Reutelingsperger; Mauro Perretti; Charles A Parkos; Omid C Farokhzad; Andrew S Neish; Asma Nusrat
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

3.  Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.

Authors:  Vincenzo Brancaleone; Jesmond Dalli; Stefania Bena; Roderick J Flower; Giuseppe Cirino; Mauro Perretti
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

Review 4.  Multiple roles for neutrophils in atherosclerosis.

Authors:  Oliver Soehnlein
Journal:  Circ Res       Date:  2012-03-16       Impact factor: 17.367

Review 5.  Annexins: linking Ca2+ signalling to membrane dynamics.

Authors:  Volker Gerke; Carl E Creutz; Stephen E Moss
Journal:  Nat Rev Mol Cell Biol       Date:  2005-06       Impact factor: 94.444

6.  Presence of lipocortins I and IV, but not II and VI, in human platelets.

Authors:  J A Eldering; M Kocher; J M Clemetson; K J Clemetson; F J Frey; B M Frey
Journal:  FEBS Lett       Date:  1993-03-08       Impact factor: 4.124

7.  Macrophages are required for neonatal heart regeneration.

Authors:  Arin B Aurora; Enzo R Porrello; Wei Tan; Ahmed I Mahmoud; Joseph A Hill; Rhonda Bassel-Duby; Hesham A Sadek; Eric N Olson
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

8.  IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein.

Authors:  E Solito; C de Coupade; L Parente; R J Flower; F Russo-Marie
Journal:  Cytokine       Date:  1998-07       Impact factor: 3.861

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

10.  Anti-allergic cromones inhibit histamine and eicosanoid release from activated human and murine mast cells by releasing Annexin A1.

Authors:  Samia Yazid; Ajantha Sinniah; Egle Solito; Virginia Calder; Rod J Flower
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240
View more
  17 in total

1.  Atheroma Niche-Responsive Nanocarriers for Immunotherapeutic Delivery.

Authors:  Erica B Peters; Nick D Tsihlis; Mark R Karver; Stacey M Chin; Bruno Musetti; Benjamin T Ledford; Edward M Bahnson; Samuel I Stupp; Melina R Kibbe
Journal:  Adv Healthc Mater       Date:  2019-01-08       Impact factor: 9.933

2.  Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure.

Authors:  Fadi W Adel; Aruna Rikhi; Siu-Hin Wan; Seethalakshmi R Iyer; Hrishikesh Chakraborty; Steven McNulty; W H Wilson Tang; G Michael Felker; Michael M Givertz; Horng H Chen
Journal:  J Card Fail       Date:  2020-05-27       Impact factor: 5.712

3.  In Vivo Developmental Trajectories of Human Podocyte Inform In Vitro Differentiation of Pluripotent Stem Cell-Derived Podocytes.

Authors:  Tracy Tran; Nils O Lindström; Andrew Ransick; Guilherme De Sena Brandine; Qiuyu Guo; Albert D Kim; Balint Der; Janos Peti-Peterdi; Andrew D Smith; Matthew Thornton; Brendan Grubbs; Jill A McMahon; Andrew P McMahon
Journal:  Dev Cell       Date:  2019-07-01       Impact factor: 12.270

4.  Differentially expressed proteins in positive versus negative HNSCC lymph nodes.

Authors:  Alessandra Vidotto; Giovana M Polachini; Marina de Paula-Silva; Sonia M Oliani; Tiago Henrique; Rossana V M López; Patrícia M Cury; Fabio D Nunes; José F Góis-Filho; Marcos B de Carvalho; Andréia M Leopoldino; Eloiza H Tajara
Journal:  BMC Med Genomics       Date:  2018-08-29       Impact factor: 3.063

5.  Modified LDL Particles Activate Inflammatory Pathways in Monocyte-derived Macrophages: Transcriptome Analysis.

Authors:  Alexander N Orekhov; Yumiko Oishi; Nikita G Nikiforov; Andrey V Zhelankin; Larisa Dubrovsky; Igor A Sobenin; Alexander Kel; Daria Stelmashenko; Vsevolod J Makeev; Kathy Foxx; Xueting Jin; Howard S Kruth; Michael Bukrinsky
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

6.  PR3 levels are impaired in plasma and PBMCs from Arabs with cardiovascular diseases.

Authors:  Abdelkrim Khadir; Dhanya Madhu; Sina Kavalakatt; Preethi Cherian; Monira Alarouj; Abdullah Bennakhi; Jehad Abubaker; Ali Tiss; Naser Elkum
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

Review 7.  Potential Impact of MicroRNA Gene Polymorphisms in the Pathogenesis of Diabetes and Atherosclerotic Cardiovascular Disease.

Authors:  Imadeldin Elfaki; Rashid Mir; Mohammad Muzaffar Mir; Faisel M AbuDuhier; Abdullatif Taha Babakr; Jameel Barnawi
Journal:  J Pers Med       Date:  2019-11-25

Review 8.  The crosstalk of ABCA1 and ANXA1: a potential mechanism for protection against atherosclerosis.

Authors:  Xin Shen; Shun Zhang; Zhu Guo; Dongming Xing; Wujun Chen
Journal:  Mol Med       Date:  2020-09-07       Impact factor: 6.354

9.  Annexin A1 Regulates NLRP3 Inflammasome Activation and Modifies Lipid Release Profile in Isolated Peritoneal Macrophages.

Authors:  José Marcos Sanches; Laura Migliari Branco; Gustavo Henrique Bueno Duarte; Sonia Maria Oliani; Karina Ramalho Bortoluci; Vanessa Moreira; Cristiane Damas Gil
Journal:  Cells       Date:  2020-04-09       Impact factor: 6.600

10.  Therapeutic Treatment Approaches Post-Myocardial Infarction: A Bias Toward Formyl Peptide Receptor Agonists.

Authors:  Rysa Zaman; Slava Epelman
Journal:  JACC Basic Transl Sci       Date:  2019-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.